116 Results for "

Hepatic fibrosis

" in MedChemExpress (MCE) Product Catalog:
Products (116)

116 Results for "Hepatic fibrosis" in MCE Product Catalog:

  • Targets Recommended:
32
32 Publications Verification
Cat. No.: HY-Y0682
CAS No.: 60-00-4
Synonyms: EDTA
Ethylenediaminetetraacetic acid (EDTA) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research .
loading...
    loading...
31
31 Cited Publications
Cat. No.: HY-B1009
CAS No.: 150-38-9
Synonyms: EDTA trisodium salt; Trisodium EDTA
Ethylenediaminetetraacetic acid trisodium salt (EDTA trisodium salt; Trisodium EDTA) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid trisodium salt has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid trisodium salt decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid trisodium salt can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research .
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-Y0682A
CAS No.: 6381-92-6
Synonyms: EDTA disodium dihydrate
Ethylenediaminetetraacetic acid (EDTA) disodium dehydrate is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid disodium dehydrate has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid disodium dehydrate decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid disodium dehydrate can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid disodium dehydrate can be used for coronary artery disease and neural system disease research .
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-W127774
CAS No.: 85715-60-2
Synonyms: Ethylenediaminetetraacetic acid hydrate sodium
EDTA (Ethylenediaminetetraacetic acid) hydrate sodium is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). EDTA hydrate sodium has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. EDTA hydrate sodium decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. EDTA hydrate sodium can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research .
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-Y0682B
CAS No.: 64-02-8
Synonyms: EDTA tetrasodium
Ethylenediaminetetraacetic acid (EDTA) tetrasodium is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid tetrasodium has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid tetrasodium decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid tetrasodium can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid tetrasodium can be used for coronary artery disease and neural system disease research .
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-W087947
CAS No.: 65501-24-8
Synonyms: Ethylenediaminetetraacetic acid dihydrate tripotassium
EDTA dihydrate tripotassium (Ethylenediaminetetraacetic acid dihydrate tripotassium) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). EDTA dihydrate tripotassium has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. EDTA dihydrate tripotassium decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. EDTA dihydrate tripotassium can alleviate the liver fibrosis. EDTA dihydrate tripotassium can be used for coronary artery disease and neural system disease research .
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-W105700
CAS No.: 10378-23-1
Synonyms: EDTA sodium hydrate
Ethylenediaminetetraacetic acid (EDTA) sodium hydrate is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid sodium hydrate has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid sodium hydrate decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid sodium hydrate can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid sodium hydrate can be used for coronary artery disease and neural system disease research .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-P0299
CAS No.: 283609-79-0
Target:  

TGF-β Receptor

Research Areas:  

Cancer

LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-P0299A
CAS No.: 2828433-17-4
Target:  

TGF-β Receptor

Research Areas:  

Cancer

LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-129389
CAS No.: 3554-93-6
Purity:  99.95%
Target:  

Glycosyltransferase

Research Areas:  

Cancer

Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, which has good potential for investigation in liver fibrosis. Benzyl-α-GalNAc also significantly enhances the anti-tumour activity of 5-Fluorouracil (HY-90006) (e.g. pancreatic cancer) by inhibiting O-glycosylation .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-B1588
CAS No.: 5697-56-3
Carbenoxolone is a blood-brain barrier-permeable Pannexin1 inhibitor, gap junction (Gap junction) blocker, and β-amyloid 42 inhibitor. Carbenoxolone modulates voltage-gated currents of wild-type and mutant Panx1, and inhibits stimulus-activated Panx1 channel function. Carbenoxolone interacts with stable residues of β-amyloid 42 peptides, fibrils and oligomers, thereby inhibiting their aggregation. Carbenoxolone alleviates liver fibrosis. Carbenoxolone exerts neuroprotective and nootropic effects. Carbenoxolone can be used in studies related to Alzheimer's disease and liver fibrosis .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-N9933
CAS No.: 25696-60-0
Synonyms: TβMCA
Tauro-β-muricholic acid (TβMCA) is an orally active trihydroxylated bile acid and a competitive, reversible FXR antagonist (IC50=40 μM). Tauro-β-muricholic acid inhibits bile acid-induced hepatocyte apoptosis by maintaining mitochondrial membrane potential, while simultaneously inhibiting intestinal FXR signaling, affecting bile acid synthesis, hepatic lipid metabolism, and insulin sensitivity. Accumulation of tauro-β-muricholic acid disrupts metabolic homeostasis, promoting cancer stem cell proliferation and tumor progression. The mechanisms of tauro-β-muricholic acid involve two aspects: first, inhibiting the translocation of the pro-apoptotic protein Bax to mitochondria and maintaining mitochondrial membrane potential (MMP); and second, blocking the FXR signaling pathway to regulate bile acid metabolism, reduce serum ceramide production, and downregulate the hepatic SREBP1C/CIDEA pathway. Tauro-β-muricholic acid possesses anti-hepatocyte apoptosis, bile acid homeostasis regulation, and liver fat accumulation reduction properties, and also functions as a biomarker, making it useful in the study of diseases such as bile acid metabolism disorders, non-alcoholic fatty liver disease, colorectal cancer, and liver fibrosis .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-151427
CAS No.: 2348795-14-0
Purity:  99.47%
Target:  

TGF-β Receptor

Research Areas:  

Inflammation/Immunology

TGFβ1-IN-1 (compound 42) is a potent, orally active TGF-β1 inhibitor. TGFβ1-IN-1 inhibits the upregulation of TGF-β1-induced fibrosis markers (α-SMA and fibronectin) and can be used in liver fibrosis disease studies .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-124748A
CAS No.: 2703451-51-6
Purity:  98.33%
ENMD-1068 hydrochloride is a selective protease-activated receptor 2 (PAR2) antagonist. ENMD-1068 hydrochloride reduces hepatic stellate cell activation and collagen expression by inhibiting TGF-β1/Smad signaling. ENMD-1068 hydrochloride also inhibits the proliferation of endometrial cells and induces apoptosis of epithelial cells in the lesion. ENMD-1068 hydrochloride can be used in the study of endometriosis and liver fibrosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P1624
CAS No.: 197922-42-2
Synonyms: ALX-0600
Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-E70226
CAS No.: 71965-46-3
Synonyms: CTSS
Human Cathepsin S (CTSS) is a cysteine protease with elastinolytic activity. Human Cathepsin S is inhibited by cysteine protease inhibitors such as E-64 (HY-15282) and cystatin C. Human Cathepsin S cleaves substrates including elastin, TGF-β1, Myelin basic protein (HY-P1821), PAR2, SIRT1, collagen 18A1, FKN, and MHC-II invariant chain fragments, thereby driving processes such as elastic matrix degradation, TGF-β1 signaling, demyelination, PAR2-mediated calcium mobilization, NF-κB activation, hepatic fibrosis, immune homeostasis regulation, and antigen presentation. Human Cathepsin S can be used in the research of cardiovascular diseases, chronic kidney diseases, autoimmune diseases, tumors, Alzheimer's disease, and obesity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0912
CAS No.: 81720-08-3
Rehmannioside D is an orally active Sirt7 modulator. Rehmannioside D upregulates Sirt7 expression, inhibits the level of acetylated p53, and blocks the activation of the p53 signaling pathway. Rehmannioside D alleviates liver injury, inflammatory response, collagen deposition and hepatocyte apoptosis. Rehmannioside D is applicable to research related to liver fibrosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-100438
CAS No.: 851518-71-3
Purity:  99.92%
Hydronidone is an orally active pyridine derivative. Hydronidone is an inhibitor of phosphodiesterase-4 (PDE4) and cyclo-oxygenase (COX) as well as TGF-β. Hydronidone induces mitochondrial dysfunction and triggers apoptosis. Hydronidone can be used for liver fibrosis, anti-inflammation and anti-cancer study .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-19796
CAS No.: 246529-22-6
Synonyms: Aramchol; C20-FABAC
Research Areas:  

Metabolic Disease

Icomidocholic acid (Aramchol) is a lipid molecule synthesized from cholic acid and arachidic acid. Icomidocholic acid is an orally active SCD1 inhibitor and cholesterol solubilizer with antifibrotic effects. Icomidocholic acid can reduce liver fat content, dissolve cholesterol crystals and prevent gallstone formation. Icomidocholic acid can be used in the study of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-121246
CAS No.: 848353-85-5
Purity:  99.78%
Synonyms: AKF-PD
Fluorofenidone (AKF-PD) is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) .
loading...
    loading...